MYOMO, INC.
Close on Oct 19, 2026
- Market cap
- $53.37M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $11.70M | $-0.09 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | $-0.07 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | After market close | $11.40M | $-0.09 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $10.10M | $-0.09 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $9.70M | $-0.11 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $9.80M | $-0.08 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | After market close | $12.10M | $-0.01 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $9.20M | $-0.03 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue guidance | over the prior year | 10% to 15% growth | – |
| full year revenue guidance | full year | $45.00M to $47.00M | Raised |
| revenue | third quarter 2026 | 14% to 19% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Myomo filed with the SEC
Myomo Reports Second Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Myomo Appoints Joseph M. Manko to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Myomo Reports First Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Myomo Appoints William J Febbo to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Myomo Reports Third Quarter 2025 Financial and Operating Results
Material agreement · Results of operations · New financial obligation · Unregistered share sale · EX-99.1 to Form 8-K
Myomo Reports Second Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Myomo Provides Highlights of Today’s Investor & Analyst Day Event
Regulation FD disclosure · EX-99.1 to Form 8-K
Myomo Reports First Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Myomo Announces Upcoming Changes to its Board of Directors
Auditor change · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million
Results of operations · EX-99.1 to Form 8-K
MYOMO, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Material agreement · Other events · EX-99.1 to Form 8-K
MYOMO, INC. PRICES $15.0 MILLION PUBLIC OFFERING OF COMMON STOCK
Material agreement · Other events · EX-99.2 to Form 8-K
Myomo Reports Record Third Quarter Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Myomo Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics
Results of operations · EX-99.1 to Form 8-K
Myomo Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees
Other events · EX-99.1 to Form 8-K
Myomo Appoints Heather Getz to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro ®
Other events · EX-99.1 to Form 8-K
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations
Results of operations · EX-99.1 to Form 8-K
CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro ® for Review at the Upcoming HCPCS Public Meeting
Other events · EX-99.1 to Form 8-K
Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category
Other events · EX-99.1 to Form 8-K
Myomo Receives Medicare Part B Reimbursement for First MyoPro® Claims
Agreement terminated · Other events · EX-99.1 to Form 8-K
Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics
Results of operations · EX-99.1 to Form 8-K
Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue
Results of operations · EX-99 to Form 8-K
Myomo Receives Technology License Fee Payment from China Joint Venture Company
Other events · EX-99 to Form 8-K
Myomo Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Myomo Announces Initiative to Reduce Cash Burn
Other events · EX-99.1 to Form 8-K
Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog
Results of operations · EX-99.1 to Form 8-K
Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions
Results of operations · EX-99.1 to Form 8-K
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions
Other events · EX-99.1 to Form 8-K
Myomo Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee
Other events · EX-99.1 to Form 8-K
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Myomo Provides Update on MyoPro ® Insurance
Other events · EX-99.1 to Form 8-K
Myomo Third Quarter 2021 Financial
Results of operations · EX-99.1 to Form 8-K